NuVasive will pay approximately $4.5 million for the company, which NuVasive has been involved with since 2010 as a manufacturing partner. Company executives said the deal will reduce the time for NuVasive device development; all 65 ANC employees will be retained.
More Articles on Devices:
DePuy Receives FDA Supplemental Pre-Market Approval for Hip Devices
Smith & Nephew Revenue Down 4 percent in Q1, $300M Share Buyback Announced
Study: Limiting Device Company, Provider Relationships Could Hurt Innovation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.